| Literature DB >> 29347857 |
Thanchanit Thaipitakwong1, Surawej Numhom2, Pornanong Aramwit1.
Abstract
CONTEXT: Cardiometabolic risks are regarded as the crucial factors associated with type 2 diabetes (T2DM) and cardiovascular diseases (CVD). Regarding an increased attention to medicinal plants in the current healthcare system, the effects of mulberry (Morus spp., Moraceae) leaves on cardiometabolic risks have been consecutively considered in scientific research.Entities:
Keywords: Morus spp.; cardiovascular diseases; hyperglycaemia; hyperlipidaemia; hypertension; obesity; oxidative stress
Mesh:
Substances:
Year: 2018 PMID: 29347857 PMCID: PMC6130672 DOI: 10.1080/13880209.2018.1424210
Source DB: PubMed Journal: Pharm Biol ISSN: 1388-0209 Impact factor: 3.503
Chemical compositions of mulberry leaves.
| Chemical compositions | Content | References |
|---|---|---|
| Crude protein | 13.4–19.4% | (Sanchez-Salcedo et al. |
| 18.41–24.63% | (Iqbal et al. | |
| 21.24–21.66% | (Adeduntan and Oyerinde | |
| Total carbohydrate | 47.27–56.42% | (Adeduntan and Oyerinde |
| Crude fat | 4.24–6.57% | (Iqbal et al. |
| 5.31–8.02% | (Adeduntan and Oyerinde | |
| Vitamin | ||
| Ascorbic acid | 0.97–1.49 mg/g | (Iqbal et al. |
| Minerals | ||
| Nitrogen | 2.1–3.1 g/100 g | (Sanchez-Salcedo et al. |
| Phosphorus | 0.1–0.2 g/100 g | (Sanchez-Salcedo et al. |
| Potassium | 1.2–3.9 g/100 g | (Sanchez-Salcedo et al. |
| Calcium | 1.7–3.9 g/100 g | (Sanchez-Salcedo et al. |
| Sodium | 0.01 g/100 g | (Sanchez-Salcedo et al. |
| Magnesium | 0.5–1.4 g/100 g | (Sanchez-Salcedo et al. |
| Sulphur | 0.2–0.3 g/100 g | (Sanchez-Salcedo et al. |
| Iron | 119.3–241.8 mg/kg | (Sanchez-Salcedo et al. |
| Zinc | 23.9–39.5 mg/kg | (Sanchez-Salcedo et al. |
| Manganese | 35.8–90.5 mg/kg | (Sanchez-Salcedo et al. |
| Boron | 253.5–825.3 mg/kg | (Sanchez-Salcedo et al. |
| Copper | 4.2–5.9 mg/kg | (Sanchez-Salcedo et al. |
| Molybdenum | 0.8–2.3 mg/kg | (Sanchez-Salcedo et al. |
| Nickel | 1.7–5.4 mg/kg | (Sanchez-Salcedo et al. |
| Lead | 0.3–0.8 mg/kg | (Sanchez-Salcedo et al. |
| Carbon | 37.4–41.4 g/100 g | (Sanchez-Salcedo et al. |
| Lithium | 1.9–17.2 mg/kg | (Sanchez-Salcedo et al. |
| Titanium | 5.4–10.8 mg/kg | (Sanchez-Salcedo et al. |
| Organic acids | ||
| Citric acid | 32.2–105.5 mg/100 g | (Sanchez-Salcedo et al. |
| Malic acid | 43.7–72.6 mg/100 g | (Sanchez-Salcedo et al. |
Preclinical studies demonstrating biological properties of mulberry leaves.
| Mulberry leaves interventions | ||||||
|---|---|---|---|---|---|---|
| Models | Species | Solvent extracts | Preparation | Dose | Duration | References |
| Healthy rats | Water | Dried powder dissolved in distilled water | 1 g/kg | Single dose | (Kim GN et al. | |
| (A) Healthy rats | Water | Extract (0.16 g DNJ/100 g) included into the diet | 3.75 g/kg (6 mg/kg DNJ) | Single dose | (Park et al. | |
| (A) Healthy rats | Ethanol | ND | 400 and 600 mg/kg/day ( | 5 weeks | (Mohammadi and Naik | |
| (A) Healthy rats | – | Dried powder of grinded leaves (0.05 g DNJ/100 g) included into the diet | 25% of the diet ( | 8 weeks | (Park et al. | |
| (A) Healthy rats | – | Brewed tea (0.25% and 0.50%) | 4 weeks | (Wilson and Islam | ||
| (A) High fat diet-induced overweight rats | Water | Extract (0.365 ± 0.025 g/100 g) included into the diet | 5% of the diet | 6 weeks | (Kim JY et al. | |
| (A) Healthy rats | – | Brewed tea (0.25% and 0.50%) | 4 weeks | (Wilson and Islam | ||
| High cholesterol diet-fed rats | Methanol | Extract dissolved in drinking water (0.1 and 1 mg/mL) | 4 weeks | (Kobayashi et al. | ||
| STZ-induced diabetic rats | (A) Ethanol | (A) Solution | (A) 600 mg/kg | 6 weeks | (Tond et al. | |
| High fat diet-fed mice | (A) Water | Extract included into the diet | 0.5 and 1.5% of the diet | 6 weeks | (Chang et al. | |
| High fat diet-induced diabetic mice | Ethanol | Extract included into the diet | 133 and 666 mg/kg | 12 weeks | (Ann et al. | |
| High fat diet-fed mice | ND | – | Dried powder of grinded leaves included into the diet | 1 and 3% of the diet | 5 days | (Sun et al. |
| High fat diet-fed mice | (A) Water | Extract included into the diet | 0.5 and 1.5% of diet | 6 weeks | (Chang et al. | |
| High fat diet-induced diabetic mice | Ethanol | Extract included into the diet | 133 and 666 mg/kg | 12 weeks | (Ann et al. | |
| STZ-induced diabetic rats | Ethanol | Extract dissolved in distilled water | 0.25, 0.50 and 1 g/kg/day | 8 weeks | (Naowaboot, Pannangpetch, Kukongviriyapan, Kukongviriyapan, et al. | |
| Spontaneously hypertensive rats | Water | Dried powder | 0.53, 1.05 and 5.26 g/kg | (A) Single dose | (Yang et al. | |
| STZ-induced diabetic mice | – | Dried powder of grinded leaves included into the diet | 25% of the diet | 8 weeks | (Andallu and Varadacharyulu | |
| STZ-induced diabetic rats | Ethanol | Extract dissolved in distilled water | 0.25, 0.50 and 1 g/kg/day | 6 weeks | (Naowaboot, Pannangpetch, Kukongviriyapan, Kongyingyoes, et al. | |
| ISO-treated rats | Methanol | Extract suspended in distilled water | 25, 50 and 100 mg/kg | 3 weeks | (Nade et al. | |
| Murine macrophage RAW 264.7 cells | Ethanol | – | 1, 10 and 50 μg/mL | 24 hours | (Park et al. | |
| Human aortic endothelial cells | Methanol–water | – | 25, 50 and 100 μg/mL | 1 hour | (Chao et al. | |
| J774A.1 macrophage cells | (A) Water | – | 0.005–10 mg/mL | – | (Yang et al. | |
| A7r5 aortic VSMCs | Water | Dried powder suspended in distilled water | 0.05, 0.1, 0.2, 0.5 and 1.0 mg/mL | 72 hours | (Chan et al. | |
| A7r5 aortic VSMCs | (A) Water | Dried powder suspended in distilled water | (A) 0.5–2.0 mg/mL | 24 hours | (Chan et al. | |
| STZ-induced diabetic rats fed with atherosclerotic diet | Water | Extract included into diet | 100, 200 and 400 mg/kg | 30 days | (Sharma et al. | |
| High cholesterol diet-fed rabbits | (A) Water | Dried powder suspended in distilled water | 1 and 2% extract | 25 weeks | (Chan et al. | |
| ISO-induced myocardial infarction rats | Methanol | Extract suspended in distilled water | 25, 50 and 100 mg/kg | 3 weeks | (Nade et al. | |
| Myosin-induced myocarditis rats | – | Powder included into the diet | 5% w/w of the diet | 3 weeks | (Arumugam et al. | |
ND: not defined; STZ: streptozotocin.
Clinical studies demonstrating clinical efficacy of mulberry leaves.
| Mulberry leaf interventions | ||||||||
|---|---|---|---|---|---|---|---|---|
| Design | Populations (N) | Species | Solvent extracts | Preparation | Dose | Duration | Outcomes | References |
| Parallel, double-blinded, RCT | Healthy volunteers (24) | Ethanol–water | DNJ-enriched powder (1.5% DNJ) dissolved in water | 0.4, 0.8 and 1.2 g (equivalent to 6, 12 and 18 mg DNJ, respectively) | Single dose | PPG and postprandial insulin during sucrose tolerance test | (Kimura et al. | |
| Parallel, double-blinded, RCT | Healthy volunteers (50) | Water | Dried powder of extract (0.36% DNJ) dissolved in water | 1.25, 2.5 and 5 g (equivalent to 4.5, 9 and 18 mg DNJ, respectively) | Single dose | PPG during maltose tolerance test | (Chung et al. | |
| Cross-over, double-blinded, RCT | Patients with impaired glucose metabolism (baseline FPG 100–140 mg/dL) (12) | Ethanol–water | DNJ-enriched powder (1.5% DNJ) in capsule | 3, 6 and 9 mg DNJ | Single dose | PPG during high-carbohydrate meal tolerance test | (Asai et al. | |
| Cross-over, double-blinded, RCT | (A) Healthy volunteers (10) | ND | Extract dissolved in water | 1 g | Single dose | PPG during sucrose tolerance test and breath hydrogen concentration | (Mudra et al. | |
| Parallel, double-blinded, RCT | Patients with T2DM (48) | ND | – | Brewed tea | 70 mL | Single dose | PPG during high-carbohydrate meal tolerance test | (Banu et al. |
| Parallel, single-blinded, RCT | (A) Healthy volunteers (10) | ND | ND | 3.3 g of extract (0.77% DNJ) included into jelly | 254 µg DNJ | Single dose | PPG, postprandial insulin, HOMA-IR and breath hydrogen concentration | (Nakamura et al. |
| Parallel, double-blinded, RCT | Healthy volunteers (12) | Ethanol–water | DNJ-enriched powder (1.5% DNJ) dissolved in water | 1.2 g (equivalent to 18 mg DNJ) thrice daily before meals | 38 days | FPG and FPI | (Kimura et al. | |
| Parallel, double-blinded, RCT | Prediabetic subjects (42) | Water | Tablet (0.36% DNJ) | 6 tablets (equivalent to 6 mg DNJ) thrice daily with meals | 4 weeks | PPG, postprandial insulin and postprandial c-peptide | (Kim et al. | |
| Cross-over, double-blinded, RCT | Patients with impaired glucose metabolism (baseline FPG 110–140 mg/dL) (76) | Ethanol–water | DNJ-enriched powder (1.5% DNJ) in capsule | 3 capsules (equivalent to 6 mg DNJ) thrice daily before meals | 12 weeks | FPG, FPI, HbA1c, glycated albumin and 1,5-AG | (Asai et al. | |
| Repeated measures, single group study | Patients with mild dyslipidaemia (baseline LDL-C 140–189 mg/dL) (23) | ND | Tablet (0.367 mg DNJ/tablet) | 3 tablets thrice daily before meals | 12 weeks | Plasma TC, LDL-C, HDL-C and TG | (Aramwit et al. | |
| Repeated measures, single group study | Patients with hypertriglyceridemia (baseline TG ≥200 mg/dL) (10) | ND | ND | Capsule (4 mg DNJ/capsule) | 3 capsules (equivalent to 12 mg DNJ) thrice daily before meals | 12 weeks | Plasma TC, LDL-C, HDL-C, TG, adiponectin, leptin and apolipoprotein-B | (Kojima et al. |
| Parallel, open-labelled, RCT | Patients with dyslipidaemia (baseline TC ≥200, LDL-C 101–190 or TG ≥150 mg/dL) (46) | – | Brewed tea | 2 g | 8 weeks | Plasma TC, LDL-C, HDL-C and TG | (Banchobphutsa | |
| Parallel, open-labelled, RCT | Patients with mild T2DM (12) | ND | Capsule (500 mg/capsule) | 2 capsules thrice daily before meals | 4 weeks | Plasma TC, LDL-C, HDL-C and TG | (Andallu et al. | |
| Parallel, open-labelled, RCT | Patients with mild T2DM (12) | ND | Capsule (500 mg/capsule) | 2 capsules thrice daily before meals | 4 weeks | Plasma-, erythrocyte membrane-, urine-peroxides | (Andallu et al. | |
| Repeated measures, single group study | Patients with mild dyslipidaemia (baseline LDL-C 140–189 mg/dL) (25) | ND | Tablet (0.367 mg DNJ/tablet) | 3 tablets thrice daily before meals | 12 weeks | Erythrocyte glutathione peroxidase activity, 8-isoprostane and CRP | (Aramwit et al. | |
ND: not defined; RCT: randomized controlled trial; HOMA-IR: homeostasis of model assessment of insulin resistance; FPI: fasting plasma insulin.